Iovance Biotherapeutics announces clinical data for lifileucel at ESMO Congress

Iovance Biotherapeutics announced the publication of an abstract reporting clinical data for lifileucel which will be presented at the European Society for Medical Oncology ESMO Congress 2023, October 20-24, 2023 in Madrid, Spain. The abstract reports outcomes of a subset of 12 patients with advanced mucosal melanoma treated with lifileucel in the pooled consecutive cohorts from the C-144-01 trial. All patients had progressed on or after immune checkpoint inhibitor therapy. Patients with mucosal melanoma, which is rare and difficult to treat, have worse outcomes after anti-PD-1 therapy compared to patients with other melanoma subtypes. The ORR assessed by an independent review committee using RECIST v1.1 was 50%. At median study follow-up of 35.7 months, median duration of response was not reached, median progression free survival was NR, and median overall survival was 19.4 months. Treatment emergent adverse events were consistent with known safety profiles of lymphodepleting chemotherapy and interleukin-2.